Tuesday, May 19, 2026

Philips CPAP and Hair Relaxer Dockets Anchor Daily Mass Tort Filings

Federal dockets captured 157 new mass tort complaints in today's report, driven predominantly by a surge of activity in established product liability dockets. The Philips CPAP Litigation (MDL 3014) led all dockets with 66 new filings, with Dicello Levitt LLP accounting for the full intake, as plaintiffs continue to allege severe respiratory and oncological injuries stemming from the degradation of polyurethane foam in recalled sleep apnea machines.

Maintaining a robust pace of intake, the Hair Relaxer Litigation (MDL 3060) added 23 new cases to its docket. These actions center on claims that prolonged exposure to endocrine-disrupting chemicals in chemical hair straighteners causes uterine, ovarian, and endometrial cancers. Meanwhile, plaintiffs lodged 13 new complaints in the rapidly expanding GLP-1 Litigation (MDL 3094), where actions center on allegations that blockbuster weight-loss and diabetes therapeutics trigger severe gastrointestinal paralysis, or gastroparesis.

Legacy and emerging pharmaceutical dockets rounded out today's heaviest activity. The J&J Talc Litigation (MDL 2738) captured 12 new filings from plaintiffs pressing claims linking talcum powder to ovarian cancer amidst the manufacturer's ongoing corporate restructuring battles. Concurrently, the newly formed Depo-Provera Litigation (MDL 3140) secured 10 new filings asserting that the injectable contraceptive significantly increases the risk of developing intracranial meningiomas. As plaintiff leadership aggressively screens for highly specialized pharmaceutical injuries, practitioners must watch whether emerging dockets like GLP-1 and Depo-Provera will rapidly close the volume gap with legacy device litigations.

Risperdal Breast Cancer Litigation Emerges as Potential MDL as Research Links Antipsychotic to Elevated Cancer Risk

A growing body of peer-reviewed evidence is fueling plaintiff attorney interest in Risperdal (risperidone) and related prolactin-elevating antipsychotics as a potential next major mass tort. Three significant recent studies have substantially strengthened the scientific foundation for litigation:

A 2023 population-scale study by Rahman of 540,737 women found a 62% increased risk of breast cancer among users of high-prolactin antipsychotics like Risperdal, and a 54% increased risk for medium-prolactin drugs such as Zyprexa. A 2025 meta-analysis by Bird, synthesizing data from 15 studies covering more than one million individuals, identified a 59% increased breast cancer risk specifically attributable to Risperdal. A 2024 Swedish registry study by Solmi of 132,061 women found a 47% increased breast cancer risk after five or more years of exposure to prolactin-increasing antipsychotics including Risperdal and Zyprexa.

Risperdal was already the subject of a major MDL and state-court litigation in prior years concerning gynecomastia (abnormal breast tissue growth) in boys—litigation that resulted in billions in verdicts and settlements against Johnson & Johnson's Janssen Pharmaceuticals subsidiary. The emerging breast cancer claims represent a distinct and potentially larger plaintiff class: adult women who used the drug long-term for schizophrenia, bipolar disorder, or as an off-label adjunct treatment. Practitioners monitoring pre-MDL plaintiff screening activity and expert witness retention patterns should treat this docket as a high-probability consolidation candidate in the near to mid-term.

EPA Moves to Repeal Biden-Era Drinking Water Limits for "Forever Chemicals"

On May 18, 2026, the U.S. Environmental Protection Agency announced a sweeping proposal to repeal and delay landmark drinking water limits for per- and polyfluoroalkyl substances. Under EPA Administrator Lee Zeldin, the agency proposed rescinding the legally enforceable Maximum Contaminant Levels for four specific "forever chemicals"—GenX, PFNA, PFHxS, and PFBS—while proposing a two-year compliance extension pushing the deadline to 2031 for the two most heavily studied compounds, PFOA and PFOS. Administrator Zeldin argued the previous administration's 2024 regulations were rushed, failed to follow proper procedural steps under the Safe Drinking Water Act, and left the rules legally vulnerable to ongoing litigation in the D.C. Circuit—positioning the repeal as an effort to establish standards that can withstand those legal challenges. For practitioners navigating the sprawling Aqueous Film-Forming Foams Products Liability Litigation (MDL 2873) and related state-court environmental contamination dockets, this structural regulatory shift—which fundamentally alters the legally enforceable baseline for what constitutes "contamination"—introduces new complexities into ongoing remediation negotiations and public nuisance claims against major chemical manufacturers.